Immix Biopharma, Inc. (NASDAQ:IMMX) Sees Significant Growth in Short Interest

Immix Biopharma, Inc. (NASDAQ:IMMX) was the recipient of a large growth in short interest in the month of September. As of September 15th, there was short interest totalling 479,700 shares, a growth of 48.1% from the August 31st total of 324,000 shares. Based on an average daily volume of 148,500 shares, the short-interest ratio is presently 3.2 days. Currently, 2.9% of the company’s stock are sold short.

Analysts Set New Price Targets

Separately, HC Wainwright reissued a “buy” rating and issued a $7.00 price objective on shares of Immix Biopharma in a research note on Monday, August 19th.

Immix Biopharma Stock Down 1.9 %

Shares of NASDAQ IMMX traded down $0.03 during mid-day trading on Friday, reaching $1.56. 51,854 shares of the company were exchanged, compared to its average volume of 187,156. Immix Biopharma has a 1 year low of $1.52 and a 1 year high of $7.75. The firm has a 50-day moving average of $1.99 and a 200 day moving average of $2.23. The stock has a market cap of $41.21 million, a price-to-earnings ratio of -1.68 and a beta of 0.17.

Immix Biopharma (NASDAQ:IMMX) last released its quarterly earnings results on Monday, August 12th. The company reported ($0.15) EPS for the quarter, beating the consensus estimate of ($0.21) by $0.06. On average, equities analysts forecast that Immix Biopharma will post -0.64 earnings per share for the current year.

Institutional Investors Weigh In On Immix Biopharma

Several institutional investors have recently bought and sold shares of IMMX. Jump Financial LLC purchased a new stake in shares of Immix Biopharma during the 4th quarter valued at $128,000. Tritonpoint Wealth LLC purchased a new stake in Immix Biopharma in the first quarter valued at about $75,000. Invst LLC acquired a new stake in Immix Biopharma in the second quarter worth about $57,000. Finally, Tocqueville Asset Management L.P. grew its stake in shares of Immix Biopharma by 89.0% during the first quarter. Tocqueville Asset Management L.P. now owns 37,800 shares of the company’s stock worth $116,000 after acquiring an additional 17,800 shares during the last quarter. 11.26% of the stock is currently owned by institutional investors and hedge funds.

About Immix Biopharma

Immix Biopharma, Inc, a clinical-stage biopharmaceutical company, engages in developing tissue-specific therapeutics in oncology and inflammation in the United States and Australia. The company is developing IMX-110 that is in Phase 1b/2a clinical trials for the treatment of soft tissue sarcoma and solid tumors; IMX-111, a tissue-specific biologic for the treatment of colorectal cancers; and IMX-120, a tissue-specific biologic for the treatment of ulcerative colitis and severe Crohn's disease.